Cargando…

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumour and has poor prognosis. Currently, systematic chemotherapy is the only approach to prolong survival. Thus the development of new treatment regimens is urgently needed to improve the therapeutic efficacy. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Li, Zhu, Yuanrun, Shao, Jinjin, Chen, Min, Yan, Hao, Li, Guanqun, Zhu, Yi, Xu, Zhifei, Yang, Bo, Luo, Peihua, He, Qiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396112/ https://www.ncbi.nlm.nih.gov/pubmed/28267710 http://dx.doi.org/10.1038/bjc.2017.55

Ejemplares similares

Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair
por: Shao, Jinjin, et al.
Publicado: (2016)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)
por: Luo, Peihua, et al.
Publicado: (2020)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
por: Koreckij, T, et al.
Publicado: (2009)

Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death
por: Li, Sainan, et al.
Publicado: (2017)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport
por: Luo, Peihua, et al.
Publicado: (2018)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
por: Vilar, E, et al.
Publicado: (2008)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage
por: Xu, Zhifei, et al.
Publicado: (2016)

α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
por: Tomasetti, M, et al.
Publicado: (2004)

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
por: Fu, Yi-Peng, et al.
Publicado: (2016)

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
por: Shen, B, et al.
Publicado: (2012)

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway
por: Chen, G, et al.
Publicado: (2014)

Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1
por: Ni, Zhongya, et al.
Publicado: (2017)

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
por: Chiu, M, et al.
Publicado: (2014)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
por: Fuh, B, et al.
Publicado: (2009)

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
por: Siveen, K S, et al.
Publicado: (2014)

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
por: Costa, F P, et al.
Publicado: (2011)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
por: Rieger-Christ, K M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_7712nek9fphdieucvu40ilg1jk